Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $27.37 million for the quarter.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, analysts expect Stoke Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $9.63 on Friday. The firm has a 50 day simple moving average of $7.90 and a 200 day simple moving average of $10.20. Stoke Therapeutics has a 52 week low of $5.35 and a 52 week high of $17.58. The company has a market cap of $525.77 million, a PE ratio of -4.59 and a beta of 1.09.

Analyst Ratings Changes

Several brokerages have recently commented on STOK. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Chardan Capital restated a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $24.67.

Insiders Place Their Bets

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 in the last three months. Insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.